Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 40
- Registration Number
- NCT01624948
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Study of Everolimus in de Novo Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Helady Pinheiro, MD, PhD
- Target Recruit Count
- 1
- Registration Number
- NCT01609673
- Locations
- 🇧🇷
Fundação IMEPEN, Juiz de Fora, MG, Brazil
🇧🇷Hospital São João de Deus/Fundação Geraldo Corrêa, Divinópolis, MG, Brazil
🇧🇷Hospital do Rim de MOntes Claros/Irmandade Nossa Senhora das Mercês, Montes Claros, MG, Brazil
A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 120
- Registration Number
- NCT01608412
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01596140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Prospective, Open Label Study of CERtican in KIdney Transplantation
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01594268
- Locations
- 🇰🇷
Novartis Investigative Site, Suwon, Korea, Republic of
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT01582009
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 153
- Registration Number
- NCT01582191
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
- Conditions
- Interventions
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 43
- Registration Number
- NCT01567488
- Locations
- 🇪🇸
Instituto Catalán de Oncologia, Hospitalet de Llobregat, Barcelona, Spain
A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 73
- Registration Number
- NCT01566279
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Noord Holland, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Zuid Holland, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
- Conditions
- Interventions
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT01563354
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.